Journal
JOURNAL OF TRANSLATIONAL MEDICINE
Volume 21, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12967-023-04080-z
Keywords
-
Categories
Ask authors/readers for more resources
In this study, the combined antitumor activity of FAP-targeted and CLDN18.2-targeted CAR-T cells against PDAC was explored. The results showed that prior infusion of FAP-targeted CAR-T cells could eliminate CAFs and enhance the anti-PDAC efficacy of subsequently infused CLDN18.2-targeted CAR-T cells. Moreover, FAP-targeted CAR-T cells could suppress the recruitment of MDSCs and promote the survival of CD8(+) T cells and CAR-T cells in tumor tissue.
Purpose The claudin 18.2 (CLDN18.2) antigen is frequently expressed in malignant tumors, including pancreatic ductal adenocarcinoma (PDAC). Although CLDN18.2-targeted CAR-T cells demonstrated some therapeutic efficacy in PDAC patients, further improvement is needed. One of the major obstacles might be the abundant cancer-associated fibroblasts (CAFs) in the PDAC tumor microenvironment (TME). Targeting fibroblast activation protein (FAP), a vital characteristic of CAFs provides a potential way to overcome this obstacle. In this study, we explored the combined antitumor activity of FAP-targeted and CLDN18.2-targeted CAR-T cells against PDAC. Methods Novel FAP-targeted CAR-T cells were developed. Sequential treatment of FAP-targeted and CLDN18.2-targeted CAR-T cells as well as the corresponding mechanism were explored in immunocompetent mouse models of PDAC. Results The results indicated that the priorly FAP-targeted CAR-T cells infusion could significantly eliminate CAFs and enhance the anti-PDAC efficacy of subsequently CLDN18.2-targeted CAR-T cells in vivo. Interestingly, we observed that FAP-targeted CAR-T cells could suppress the recruitment of myeloid-derived suppressor cells (MDSCs) and promote the survival of CD8(+) T cells and CAR-T cells in tumor tissue. Conclusion In summary, our finding demonstrated that FAP-targeted CAR-T cells could increase the antitumor activities of sequential CAR-T therapy via remodeling TME, at least partially through inhibiting MDSCs recruitment. Sequential infusion of FAP-targeted and CLDN18.2-targeted CAR-T cells might be a feasible approach to enhance the clinical outcome of PDAC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available